Spectrum Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.10.13	Spectrum Reports Completion Of Enrollment For Melphalan Pivotal Trial (RTTNews)
08.10.13	Early Briefing and Review: Arena Pharma Inc., Spectrum Pharma Inc., Incyte Corp. Ltd., and Geron Corp. (PR Newswire)
04.09.13	RMTI Awaits CRUISE-2, AVNR On A High, ENTA Gets More Funds, Watch Out For ZLCS (RTTNews)
03.09.13	Spectrum Pharma Introduces Marqibo & Ships First Commercial Orders (RTTNews)
29.07.13	Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope (PR Newswire)
29.07.13	Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope (PR Newswire)
17.07.13	Spectrum Pharma To Buy Talon Therapeutics - Quick Facts (RTTNews)
08.05.12	Spectrum Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference (Businesswire)
01.05.12	Spectrum Pharmaceuticals to Present at the Deutsche Bank 37th Annual Health Care Conference (Businesswire)
26.04.12	Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter of 2012 (Businesswire)
23.04.12	Spectrum Pharmaceuticals Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV® (Businesswire)
19.04.12	Spectrum Pharmaceuticals to Be Added to the S&P SmallCap 600 Index (Businesswire)
17.04.12	Spectrum Pharmaceuticals Announces First Quarter 2012 Financial Results Teleconference and Webcast (Businesswire)
16.04.12	Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics (Businesswire)
05.04.12	Wall Street Schluss: US-Börsen schliessen kaum verändert, Bed Bath Beyond legen nach Zahlen kräftig zu (Aktiencheck)
05.04.12	Wall Street Update: US-Börsen kaum verändert, Bed Bath Beyond nach Zahlen gefragt (Aktiencheck)
05.04.12	Wall Street Eröffnung: Verluste, Arbeitsmarktdaten und März-Umsätze im Blick, Constellation Brands knicken ein (Aktiencheck)
05.04.12	Allos Therapeutics-Aktie nach Übernahme durch Spectrum Pharmaceuticals im Fokus (Aktiencheck)
05.04.12	Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012 (Businesswire)
05.04.12	Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials (Businesswire)
27.03.12	Spectrum Announces Launch of New Patient-to-Patient Educational Campaign for ZEVALIN® on ZEVALIN.com (Businesswire)
12.03.12	Spectrum Pharmaceuticals to Present at the 24th Annual ROTH Conference (Businesswire)
01.03.12	Spectrum Pharmaceuticals Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2011 (Businesswire)
24.02.12	Spectrum Pharmaceuticals to Present at the Citi 2012 Global Health Care and the RBC Capital Markets Health Care Conferences (Businesswire)
23.02.12	Spectrum Pharmaceuticals Announces Date and Time for Its Fourth Quarter and Fiscal Year 2011 Financial Results Conference Call (Businesswire)
07.02.12	Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference (Businesswire)
31.01.12	Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals (Businesswire)
27.01.12	Spectrum Pharmaceuticals Strengthens Commercial Operations (Businesswire)
25.01.12	Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® (Businesswire)
23.01.12	ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in "CANCER”, the Journal of the American Cancer Society (Businesswire)
04.01.12	Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference (Businesswire)
12.12.11	Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications (Businesswire)
12.12.11	Multifaceted Repositioning Campaign for ZEVALIN® Unveiled at ASH 2011, Following Recent FDA Approval to Remove Bioscan Requirement (Businesswire)
09.12.11	Spectrum Pharmaceuticals Affirms Strong Patent Protection for FUSILEV® (levoleucovorin) Through December 31, 2019 (Businesswire)
09.12.11	Spectrum Pharmaceuticals Announces 19 ZEVALIN Presentations at the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 10-13, 2011 (Businesswire)
09.12.11	Ecolab China Again Named Outstanding Enterprise for Corporate Social Responsibility by China Business News (Businesswire)
07.12.11	Spectrum Pharmaceuticals to Present at the Oppenheimer & Co. 22nd Annual Healthcare Conference (Businesswire)
05.12.11	Dollar General Corporation Reports Record Third Quarter Sales and Earnings; Announces $500 Million Share Repurchase Authorization (Businesswire)
05.12.11	Spectrum Pharmaceuticals Files IND Application with U.S. FDA for SPI-014 (Businesswire)
28.11.11	Spectrum Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on Tuesday, November 29, 2011 (Businesswire)
21.11.11	FDA Approves the Removal of the Bioscan Requirement for ZEVALIN® Treatment (Businesswire)
09.11.11	Spectrum Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference (Businesswire)
01.09.11	Local.com Named Preferred Supplier to PAGE Cooperative (Businesswire)
23.02.11	Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis (Businesswire)
29.11.10	FDA Accepts for Review Spectrum’s Response on FUSILEV® as a Class 2 Submission, and Establishes April 29, 2011 as PDUFA Action Date (Businesswire)
03.11.10	Spectrum Pharmaceuticals Receives Nearly $1 Million in Grants for Qualifying Therapeutic Discovery Projects (Businesswire)
12.01.10	Spectrum Pharmaceuticals Completes Enrollment in Second of Two Phase 3 Pivotal Trials for Apaziquone in Non-Muscle Invasive Bladder Cancer (Businesswire)
12.11.09	Spectrum Pharmaceuticals Announces Third Quarter 2009 Corporate Update; ZEVALIN® Sales up 80% over Third Quarter 2008 (Businesswire)
20.10.09	Spectrum Pharmaceuticals, Inc. Ranked #22 Fastest Growing Company in North America on Deloitte’s 2009 Technology Fast 500™ (Businesswire)
13.08.09	Spectrum Pharmaceuticals Announces Second Quarter 2009 Corporate Update (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.37	2.88 %	K V
Part Grp Hldg	1’330.00	2.39 %	K V
Roche Hldg G	271.80	1.84 %	K V
Givaudan	3’941.00	1.52 %	K V
Novartis	91.64	0.75 %	K V
Geberit	502.80	-0.59 %	K V
CieFinRichemont	139.55	-0.99 %	K V
Swiss Re	133.25	-1.15 %	K V
Zurich Insur Gr	540.00	-1.32 %	K V
Kuehne+Nagel Int	203.00	-2.12 %	K V

Nachrichten zu Spectrum Pharmaceuticals IncShs

Aktien Top/Flop

Meistgelesene Nachrichten